Literature DB >> 2845354

A possible role for leukotrienes in the regulation of glomerular haemodynamics in the dog.

J Heller1, V Horácek, S Kamarádová.   

Abstract

In anaesthetized beagles, saralasin, phentolamine, 1-penicillamine-2-O-methyl-tyrosine-8-arginine-vasopressin and SCH 23390, a DA1 antagonist, were infused into the left renal artery (i.r.a.) and indomethacin and aprotinin intravenously (Group 1). In Groups 2 and 3, i.r.a. infusion of two chemically different putative leukotriene (LT) antagonists, FPL 55712 (100 micrograms/kg/min) and LY 171883 (500 micrograms/kg/min), respectively, was superimposed in the fourth period of experiments. In comparison to Group 1, there was an increase (40% in Group 2 and 33% in Group 3) in renal blood flow and a decrease in glomerular filtration rate (16% and 17%, respectively) and filtration fraction (36% and 41%, respectively). Similar changes were observed on the single nephron level. Directly measured glomerular capillary pressure decreased by 10% and 12%, respectively. A decrease in total arteriolar resistance by 34% and 25%, respectively, was caused by a comparatively higher decrease in efferent (44% and 34%, respectively) than afferent (26% and 15%, respectively) arteriolar resistance values. No change in the ultrafiltration coefficient, Kf, was detected. Providing FPL 55712 and LY 171883 are specific LT antagonists, these experiments suggest a possible constrictory role of LT (expressed more on the efferent than afferent arteriole) in anaesthetised mildly surgically stressed dogs.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2845354     DOI: 10.1007/bf00583745

Source DB:  PubMed          Journal:  Pflugers Arch        ISSN: 0031-6768            Impact factor:   3.657


  29 in total

1.  Inhibition of antigen-induced histamine release and thromboxane synthase by FPL 55712, a specific SRA-A antagonist?

Authors:  A F Welton; W C Hope; L D Tobias; J G Hamilton
Journal:  Biochem Pharmacol       Date:  1981-06-01       Impact factor: 5.858

2.  Pharmacologic receptors for the leukotrienes.

Authors:  J H Fleisch; L E Rinkema; W S Marshall
Journal:  Biochem Pharmacol       Date:  1984-12-15       Impact factor: 5.858

3.  Leukotrienes: a new class of mediators of immediate hypersensitivity reactions and inflammation.

Authors:  B Samuelsson
Journal:  Adv Prostaglandin Thromboxane Leukot Res       Date:  1983

4.  Influence of renal lipoxygenase activity on the renal vascular response to arachidonic acid.

Authors:  L P Feigen
Journal:  J Pharmacol Exp Ther       Date:  1984-01       Impact factor: 4.030

5.  Divergent influences of leukotrienes C4, D4, and E4 on mesenteric and renal blood flow.

Authors:  B M Chapnick
Journal:  Am J Physiol       Date:  1984-04

6.  Renal and systemic hemodynamic responses to intravenous infusion of leukotriene C4 in the rat.

Authors:  K F Badr; C Baylis; J M Pfeffer; M A Pfeffer; R J Soberman; R A Lewis; K F Austen; E J Corey; B M Brenner
Journal:  Circ Res       Date:  1984-05       Impact factor: 17.367

7.  Potent vasoconstriction of the isolated perfused rat kidney by leukotrienes C4 and D4.

Authors:  A Rosenthal; C R Pace-Asciak
Journal:  Can J Physiol Pharmacol       Date:  1983-04       Impact factor: 2.273

8.  Effects of leukotrienes on isolated rat glomeruli and cultured mesangial cells.

Authors:  R Barnett; P Goldwasser; L A Scharschmidt; D Schlondorff
Journal:  Am J Physiol       Date:  1986-05

9.  Lipoxygenase activity in rat kidney glomeruli, glomerular epithelial cells, and cortical tubules.

Authors:  K Jim; A Hassid; F Sun; M J Dunn
Journal:  J Biol Chem       Date:  1982-09-10       Impact factor: 5.157

10.  The actions of leukotrienes C4 and D4 in the porcine renal vascular bed.

Authors:  P J Piper; A W Stanton; L J McLeod
Journal:  Prostaglandins       Date:  1985-01
View more
  1 in total

1.  The cause of a depressed glomerular filtration rate after an ischaemic insult: whole kidney and superficial nephron study in the dog.

Authors:  J Heller; V Horácek
Journal:  Pflugers Arch       Date:  1990-12       Impact factor: 3.657

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.